Defense World
19 Jul 2026, 08:01 UTC · 14w ago
Impact · against what's priced in
Tango Therapeutics is seeing a positive catalyst from the initiation of coverage by JPMorgan and a price target hike from Mizuho, signaling increased institutional appeal. While insider selling and a neutral earnings report provide slight headwinds, the overall sentiment is driven by bullish sell-side revisions.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
JPMorgan Chase assumed coverage of Tango Therapeutics with an 'overweight' rating and a target price of $46.00.
So whatInitiation of coverage by a top-tier investment bank with a bullish price target typically attracts significant institutional interest.
More positive than 93% of claims this week
Mizuho raised its price objective for Tango Therapeutics from $36.00 to $40.00 and maintained an 'outperform' rating.
So whatAn upward revision of a price target by a major analyst indicates improving fundamentals or valuation outlook.
Continue reading
5 related stories
JPMorgan's initiation of coverage with an 'overweight' rating and a $46.00 target, combined with Mizuho raising its target to $40.00, creates positive momentum that outweighs the noise of an insider selling 27,000 shares.
Read from the article alone
No priced-in read yet
The price saw a minor positive lift attributed to a share purchase by Copeland Capital Management.
Read from the article alone
No priced-in read yet
The stock saw a 5.5% increase, though the article provides no specific fundamental driver for this movement.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 78% of claims this week
Insider Adam Crystal sold 27,000 shares of TNGX on July 1st, reducing his ownership by 18.92%.
More negative than 79% of claims this week
Tango Therapeutics reported quarterly EPS of ($0.32), meeting consensus estimates.
Near neutral — 99% of claims this week are stronger
Which stocks this story touches
More positive than 76% of ticker scores this week
Share price increased 6.1% and the company received multiple 'Buy' and 'Outperform' ratings from major analysts.
More positive than 69% of ticker scores this week
Shares increased by 5.5%.
More positive than 53% of ticker scores this week
A positive note regarding a purchase of shares by Copeland Capital Management.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
6h ago
−3.0%
Price is moving against the score
$121.85 vs $125.68 close before publication (Jul 17) · not market-adjusted
ARES chart →−22.3%
Price is moving against the score
$22.20 vs $28.56 close before publication (Jul 17) · not market-adjusted
TNGX chart →+17.1%
Price agrees with the score
$94.80 vs $80.99 close before publication (Jul 17) · not market-adjusted
ERFSF chart →
